<DOC>
	<DOC>NCT02880293</DOC>
	<brief_summary>This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.</brief_summary>
	<brief_title>Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor</brief_title>
	<detailed_description />
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>High risk hematologic malignancies Persons with a HLA matched sibling donor. Female patients who are pregnant or breastfeeding •Persons with an infection that is not responding to antimicrobial therapy •Persons who are seropositive for HIV or HTLV1/2. Persons with uncontrolled central nervous system malignancy •Persons who do not meet the age and organ function criteria specified above Presence of psychiatric or neurologic disease, or lack of social support that limits the patient's ability to comply with the treatment protocol including supportive care, followup, and research tests.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>transplant conditioning</keyword>
	<keyword>KIR/HLA based haploidentical donor selection</keyword>
	<keyword>allogeneic hematopoietic cell transplantation</keyword>
</DOC>